Cencora (NYSE:COR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Cencora (NYSE:COR) had its price target increased by JPMorgan Chase & Co. from $417.00 to $419.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 14.52% from the company’s previous close.

A number of other brokerages have also commented on COR. TD Cowen lifted their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Mizuho raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, UBS Group upped their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.92.

Cencora Stock Performance

NYSE:COR opened at $365.89 on Tuesday. The stock has a market capitalization of $70.98 billion, a P/E ratio of 43.98, a price-to-earnings-growth ratio of 1.66 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora has a 1 year low of $237.71 and a 1 year high of $377.54. The firm has a 50 day moving average of $346.79 and a 200-day moving average of $327.66.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period last year, the firm posted $3.73 EPS. The business’s revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Cencora will post 15.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 20,316 shares of company stock worth $7,151,265 over the last ninety days. Company insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. Vestcor Inc lifted its position in shares of Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock worth $1,624,000 after purchasing an additional 28 shares in the last quarter. JFS Wealth Advisors LLC increased its stake in Cencora by 30.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after buying an additional 29 shares during the last quarter. Cornerstone Wealth Group LLC increased its stake in Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after buying an additional 30 shares during the last quarter. Apollon Wealth Management LLC lifted its position in Cencora by 0.5% during the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock worth $2,205,000 after buying an additional 30 shares in the last quarter. Finally, Accent Capital Management LLC boosted its stake in shares of Cencora by 36.1% during the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock worth $38,000 after buying an additional 30 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.